UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


 
FORM 8-K


 
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): June 14, 2017


 
PHARMERICA CORPORATION
(Exact Name of Registrant as Specified in Its Charter)


 
Delaware
001-33380
87-0792558
     
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
 
1901 Campus Place
Louisville, Kentucky 40299
(Address of principal executive offices) (Zip Code)
 
(502) 627-7000
(Registrant’s telephone number, including area code)


 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 


Item 5.07
Submission of Matters to a Vote of Security Holders.
 
The 2017 Annual Meeting of Stockholders of PharMerica Corporation (the “Company”) was held on June 14, 2017.
 
1.
The Company’s stockholders approved the election of the following seven directors for a term to expire at the Annual Meeting of Stockholders in 2018. The votes for each director were as follows:

Name
 
For
   
Withheld
Authority
   
Broker Non-
Votes
 
Frank E. Collins, Esq.
   
26,260,958
     
145,961
     
3,402,081
 
W. Robert Dahl, Jr.
   
26,314,884
     
92,035
     
3,402,081
 
Marjorie W. Dorr
   
26,322,611
     
84,308
     
3,402,081
 
Patrick G. LePore
   
26,295,796
     
111,123
     
3,402,081
 
Geoffrey G. Meyers
   
26,301,570
     
105,349
     
3,402,081
 
Robert A. Oakley, Ph.D.
   
26,313,704
     
93,215
     
3,402,081
 
Gregory S. Weishar
   
26,317,775
     
89,144
     
3,402,081
 

2.
The Company’s stockholders voted upon the ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2017. The votes on this proposal were as follows:

For
 
Against
 
Abstained
29,719,945
 
81,839
 
7,216

3.
The Company’s stockholders voted upon and approved, by advisory vote, the compensation of the Company’s named executive officers. The votes on this proposal were as follows:

For
 
Against
 
Abstained
 
Broker Non-Votes
25,173,015
 
1,181,809
 
52,095
 
3,402,081
 

4.
The Company’s stockholders voted upon and approved, by advisory vote, one year as the frequency of the advisory vote on executive compensation in future years. The votes on this proposal were as follows:

One Year
 
Two Years
 
Three Years
 
Abstained
 
Broker Non-Votes
19,874,255
 
11,468
 
6,475,964
 
45,232
 
3,402,081

5.
The Company’s stockholders voted upon and approved, by advisory vote, a stockholder proposal regarding simple majority vote. The votes on this proposal were as follows:

For
 
Against
 
Abstained
 
Broker Non-Votes
23,545,772
 
2,803,577
 
57,570
 
3,402,081
 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
PHARMERICA CORPORATION
   
Date: June 19, 2017
By:
/s/ Thomas Caneris
 
   
Thomas Caneris
 
       
   
Senior Vice President, General Counsel and Secretary